A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

NCT02367456 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia

Interventions

DRUG: PF-04449913 (Glasdegib)
DRUG: Azacitidine

Sponsor

Pfizer